New AGA/AASLD Guideline Issues 6 Recommendations on PBC Management

The AGA and AASLD convened a multidisciplinary panel to issue evidence-based recommendations on primary biliary cholangitis (PBC) management, using GRADE methodology. The guideline addresses six areas: PBC-specific antinuclear antibodies for antimitochondrial antibody-negative suspected PBC, ursodeoxycholic acid (UDCA) as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator-activated receptor agonists for inadequate UDCA response or intolerance, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The panel notes certainty of evidence ranged from moderate to very low across recommendations.

Most relevant for: Adults with primary biliary cholangitis, including those with antimitochondrial antibody-negative disease, inadequate response to UDCA, cholestatic pruritus, or prior liver transplantation.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.